Ascent Biomedical Ventures

Peerbridge Health Inc. is a digital health company based in New York that specializes in remote monitoring of vital signs through its innovative wireless electrocardiogram (ECG) technology. The company has developed Peerbridge Cor, a multi-channel ECG monitor that provides physicians with real-time heart data and captures critical insights over a continuous seven-day period to aid in arrhythmia detection. In addition to Peerbridge Cor, the company offers Peerbridge CorHRV and Peerbridge Cor+, which monitor various vital signs including heart rate, respiratory rate, temperature, oxygen saturation, and heart rate variability (HRV). Peerbridge Health holds two patents related to medical-grade monitoring of vital signs, with additional patents pending, reflecting its commitment to enhancing healthcare delivery and patient outcomes through advanced technology. Founded in 2012, the company aims to improve the independence and precision of remote health monitoring for both medical and wellness applications.

CuraSeal, Inc. is a company based in Santa Clara, California, that specializes in designing and manufacturing interventional devices aimed at treating disorders of the gastrointestinal tract. Founded in 2007, CuraSeal focuses on developing regenerative medical technologies that restore the structure and function of damaged tissues and organs. Their innovative products integrate tissue engineering with minimally invasive techniques, offering advanced solutions such as collagen, antimicrobial chemotherapy, growth factors, and cell-based therapies. Through these next-generation devices and therapeutics, CuraSeal aims to enhance patient quality of life by providing effective treatment options for gastrointestinal conditions.

eCaring offers a web-based home care monitoring and management system designed to enhance communication between care managers, providers, and family members. The platform enables home health aides, patients, and family members to document vital health information, including physical and mental states, medication adherence, and other significant behaviors in real-time. This data collection allows healthcare providers to identify issues and respond promptly, thereby preventing hospital readmissions and improving overall patient outcomes. eCaring consists of several interrelated products, including CareTracker, which facilitates the entry of detailed health information, CareJournal, which provides a comprehensive view of patient data, and CarePortrait, which offers insights into clinically significant trends over time. Additionally, CareAlerts, currently in development, will notify users of critical health changes via email and SMS. By streamlining home healthcare management, eCaring aims to increase care coordination, enhance provider productivity, and reduce stress for patients and their families.

Covagen is a biopharmaceutical company that specializes in developing bispecific FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach results in therapeutics with unique modes of action and improved efficacy for treating inflammatory diseases and cancer. Covagen's lead product, COVA322, targets inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company's proprietary platform allows for the customization of FynomAbs by attaching Fynomers at multiple sites on an antibody, enabling tailored therapeutic architectures. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic partnerships, including a collaboration with Mitsubishi Tanabe for developing bispecific FynomAbs against specific target pairs. The company is backed by a consortium of investors, which includes notable names in the life sciences sector.

Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.

Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.

Developer of therapeutic drugs designed to prevent stress induced diseases. The company's drugs curb a disease-related biochemical condition called oxidative stress and specifically targets oxidized cystine residues of key proteins involved in human diseases, enabling patients to get advanced medicines for their diseases that help them to recover faster.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.

Ouroboros, Inc. is a San Diego-based company that specializes in the manufacturing of spine products designed to treat degenerated disc disease. The company focuses on developing innovative solutions to address the challenges associated with spinal health, aiming to improve patient outcomes through its specialized medical devices.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, that specializes in the design and development of non-fusion motion preservation systems aimed at treating degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both of which replicate the anatomical and biomechanical properties of natural intervertebral discs. This innovative approach allows for the incorporation of an artificial nucleus and annulus, providing surgeons with a practical option for disc replacement. Spinal Kinetics distributes its products through a network of distributors across multiple countries, including Australia, Canada, several European nations, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.

Entigo specializes in enterprise warranty chain management solutions, providing businesses with tools to streamline warranty processing. Its primary offerings include Entigo Warranty, which facilitates the management of warranty claims, and Entigo Catalyst, designed for strategic assessments of existing warranty operations. The company also offers a range of services such as project management, implementation consulting, and systems integration. These solutions aim to automate the registration and claims process, reduce error rates, and enhance analytics for informed decision-making, ultimately improving product quality and minimizing warranty costs. Entigo's systems are tailored to meet the needs of Fortune 500 manufacturers across various sectors, including automotive, aerospace, and industrial equipment. Founded in 1995 and headquartered in Exton, Pennsylvania, Entigo is committed to optimizing warranty processes and ensuring seamless integration with warranty chain partners.